N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement
Barbara E. Stähli MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.
Search for more papers by this authorCathérine Gebhard MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.
Search for more papers by this authorLanja Saleh PhD
Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorVolkmar Falk MD
Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorUlf Landmesser MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorFabian Nietlispach MD, PhD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorFrancesco Maisano MD
Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorThomas F. Lüscher MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorWillibald Maier MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorCorresponding Author
Ronald K. Binder MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Correspondence to: Ronald K. Binder, MD, Department of Cardiology, University Heart Center Zurich, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. E-mail: [email protected]Search for more papers by this authorBarbara E. Stähli MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.
Search for more papers by this authorCathérine Gebhard MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Barbara E. Stähli and Cathérine Gebhard contributed equally to this work.
Search for more papers by this authorLanja Saleh PhD
Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorVolkmar Falk MD
Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorUlf Landmesser MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorFabian Nietlispach MD, PhD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorFrancesco Maisano MD
Departement of Cardiovascular Surgery, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorThomas F. Lüscher MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorWillibald Maier MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Search for more papers by this authorCorresponding Author
Ronald K. Binder MD
Department of Cardiology, University Heart Center, Zurich, Switzerlan
Correspondence to: Ronald K. Binder, MD, Department of Cardiology, University Heart Center Zurich, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. E-mail: [email protected]Search for more papers by this authorConflict of interest: Dr Nietlispach is a proctor for Edwards Lifesciences, Dr. Binder is a consultant to Edwards Lifesciences. All other authors have no conflicts of interest to declare.
Abstract
Objectives
We studied the prognostic value of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is independent of individual cutoff levels, in predicting mortality in patients undergoing transcatheter aortic valve replacement (TAVR). Background: Elevated levels of natriuretic peptides are associated with adverse outcomes across a wide spectrum of cardiovascular diseases. However, cutoff values differ according to age, gender, and body weight. Methods: 244 TAVR patients with preprocedural NT-proBNP levels were analyzed, and the predictive value of NT-proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values specific for age and gender) on all-cause-mortality was assessed in a multivariate model. Results: Median NT-proBNP-ratio was 4.2 [IQR 1.8–9.7]. All-cause mortality at 30 days was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients with more than median NT-proBNP-ratio (P = 0.02). All-cause mortality at 1 year was 8.5% in patients with less than median NT-proBNP-ratio, and 32.1% in those with more than median NT-proBNP-ratio (P = 0.001). Cumulative survival declined with increasing quartiles of NT-proBNP-ratio (log rank P = 0.001). All patients with a NT-proBNP-ratio below 1.5 survived at 1-year follow-up. In ROC analysis, NT-proBNP-ratio significantly predicted 30-day (AUC = 0.72; P = 0.002) and 1-year all-cause mortality (AUC = 0.72; P < 0.001). By multivariate Cox regression analysis, NT-proBNP-ratio, chronic obstructive pulmonary disease, and serum creatinine were the only independent predictors of all-cause mortality. Conclusions: Elevated NT-proBNP-ratio was associated with increased short- and long-term mortality after TAVR, and independently predicted all-cause mortality. NT-proBNP-ratio should be considered in the risk stratification of patients undergoing TAVR. © 2015 Wiley Periodicals, Inc.
REFERENCES
- 1 Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686–1695.
- 2 Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J, Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK, the USCCI. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790–1798.
- 3 Toggweiler S, Humphries KH, Lee M, Binder RK, Moss RR, Freeman M, Ye J, Cheung A, Wood DA, Webb JG. 5 year outcome after transcatheter aortic valve implantation. J Am Coll Cardiol 2013; 61: 413–419.
- 4 Stahli BE, Tasnady H, Luscher TF, Gebhard C, Mikulicic F, Erhart L, Buhler I, Landmesser U, Altwegg L, Wischnewsky MB, Grunenfelder J, Falk V, Corti R, Maier W. Early and late mortality in patients undergoing transcatheter aortic valve implantation: Comparison of the novel euroscore ii with established risk scores. Cardiology 2013; 126: 15–23.
- 5 Stahli BE, Grunenfelder J, Jacobs S, Falk V, Landmesser U, Wischnewsky MB, Luscher TF, Corti R, Maier W, Altwegg LA. Assessment of inflammatory response to transfemoral transcatheter aortic valve implantation compared to transapical and surgical procedures: A pilot study. J Invasive Cardiol 2012; 24: 407–411.
- 6 Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, Muller C, Vasa-Nicotera M, Grube E, Nickenig G, Werner N. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 2012; 33: 1459–1468.
- 7 Wendt D, Thielmann M, Kahlert P, Kastner S, Price V, Al-Rashid F, Patsalis P, Erbel R, Jakob H. Comparison between different risk scoring algorithms on isolated conventional or transcatheter aortic valve replacement. Ann Thorac Surg 2014; 97: 796–802.
- 8 Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL. Plasma n-terminal b-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: Comparison with plasma midregional pro-atrial natriuretic peptide: The lamp (leicester acute myocardial infarction peptide) study. J Am Coll Cardiol 2008; 51: 1857–1864.
- 9 Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, Yandle TG, French JK, Richards AM, White HD. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003; 107: 1884–1890.
- 10 Weber M, Arnold R, Rau M, Elsaesser A, Brandt R, Mitrovic V, Hamm C. Relation of n-terminal pro b-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005; 26: 1023–1030.
- 11 Solberg OG, Uel T, Wergel R, Dahl CP, Aakhus S, Aukrust P, Gullestad L. High-sensitive troponin t and n-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scand Cardiovasc J 2012; 46: 278–285.
- 12 Weber M, Hausen M, Arnold R, Nef H, Moellman H, Berkowitsch A, Elsaesser A, Brandt R, Mitrovic V, Hamm C. Prognostic value of n-terminal pro-b-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006; 92: 1639–1644.
- 13 Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, Binder T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302–2308.
- 14 Nessmith MG, Fukuta H, Brucks S, Little WC. Usefulness of an elevated b-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 2005; 96: 1445–1448.
- 15 Cimadevilla C, Cueff C, Hekimian G, Dehoux M, Lepage L, Iung B, Duval X, Huart V, Tubach F, Vahanian A, Messika-Zeitoun D. Prognostic value of b-type natriuretic peptide in elderly patients with aortic valve stenosis: The cofrasa-generac study. Heart 2013; 99: 461–467.
- 16 Ben-Dor I, Minha S, Barbash IM, Aly O, Dvir D, Deksissa T, Okubagzi P, Torguson R, Lindsay J, Satler LF, Pichard AD, Waksman R. Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis. Am J Cardiol 2013; 112: 574–579.
- 17 Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, Enriquez-Sarano M. Btype natriuretic peptide clinical activation in aortic stenosis: Impact on long-term survival. J Am Coll Cardiol 2014; 63: 2016–2025.
- 18 Stahli BE, Bunzli R, Grunenfelder J, Buhler I, Felix C, Bettex D, Biaggi P, Tanner FC, Nguyen-Kim DL, Plass A, Ge H, Falk V, Luscher TF, Corti R, Maier W, Altwegg LA. Transcatheter aortic valve implantation (tavi) outcome according to standardized endpoint definitions by the valve academic research consortium (varc). J Invasive Cardiol 2011; 23: 307–312.
- 19 Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The valve academic research consortium-2 consensus document. Eur Heart J 2012; 33: 2403–2418.
- 20 Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quinones M. Echocardiographic assessment of valve stenosis: Eae/ase recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22: 1–23.
- 21 Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. Btype natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397.
- 22 Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107: 2545–2547.
- 23 Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, Vanoverschelde JL, Carayon A, Gueret P. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: Role of b-type natriuretic peptide. Eur Heart J 2004; 25: 2048–2053.
- 24 Katz M, Tarasoutchi F, Pesaro AE, Lopes RD, Spina GS, Vieira ML, Grinberg M. Natriuretic peptides and long-term mortality in patients with severe aortic stenosis. J Heart Valve Dis 2012; 21: 331–336.
- 25 Pedrazzini GB, Masson S, Latini R, Klersy C, Rossi MG, Pasotti E, Faletra FF, Siclari F, Minervini F, Moccetti T, Auricchio A. Comparison of brain natriuretic peptide plasma levels versus logistic euroscore in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 2008; 102: 749–754.
- 26 Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J, Jr Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh J, CoreValve United States clinical I. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014; 63: 1972–1981.
- 27 Elhmidi Y, Bleiziffer S, Piazza N, Ruge H, Krane M, Deutsch MA, Hettich I, Voss B, Mazzitelli D, Lange R. The evolution and prognostic value of n-terminal brain natriuretic peptide in predicting 1-year mortality in patients following transcatheter aortic valve implantation. J Invasive Cardiol 2013; 25: 38–44.
- 28 Lopez-Otero D, Trillo-Nouche R, Gude F, Cid-Alvarez B, Ocaranza-Sanchez R, Alvarez MS, Lear PV, Gonzalez-Juanatey JR. Pro b-type natriuretic peptide plasma value: A new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation. Int J Cardiol 2013; 168: 1264–1268.
- 29 Kefer J, Beauloye C, Astarci P, Renkin J, Glineur D, Dekleermaeker A, Vanoverschelde JL. Usefulness of b-type natriuretic peptide to predict outcome of patients treated by transcatheter aortic valve implantation. Am J Cardiol 2010; 106: 1782–1786.
- 30 O'Sullivan CJ, Stortecky S, Heg D, Juni P, Windecker S, Wenaweser P. Impact of b-type natriuretic peptide on short-term clinical outcomes following transcatheter aortic valve implantation. EuroIntervention 2014 Jan 17 [Epub ahead of print].
- 31 Ribeiro HB, Urena M, Le Ven F, Nombela-Franco L, Allende R, Clavel MA, Dahou A, Cote M, Laflamme J, Laflamme L, DeLarochelliere H, DeLarochelliere R, Doyle D, Dumont E, Bergeron S, Pibarot P, Rodes-Cabau J. Long-term prognostic value and serial changes of plasma n-terminal prohormone b-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 851–859.
- 32 Pfister R, Wahlers T, Baer FM, Scherner M, Strauch J, Erdmann E. Utility of nt-pro-bnp in patients undergoing transapical aortic valve replacement. Clin Res Cardiol 2010; 99: 301–307.
- 33 Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40: 976–982.
- 34 Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, Levy D, Vasan RS, Wang TJ. Reference limits for n-terminal-pro-b-type natriuretic peptide in healthy individuals (from the Framingham heart study). Am J Cardiol 2011; 108: 1341–1345.
- 35 Detaint D, Messika-Zeitoun D, Chen HH, Rossi A, Avierinos JF, Scott C, Burnett JC, Jr, Enriquez-Sarano M. Association of b-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol 2006; 97: 1029–1034.